Altium Capital Management LP Relmada Therapeutics, Inc. Transaction History

Altium Capital Management LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$18.3 - $37.02 $356,850 - $721,890	-19,500 Reduced 69.64%	8,500 $315,000
Q2 2022 Aug 15, 2022	SELL	$16.5 - $30.34 $2.94 Million - $5.4 Million	-178,000 Reduced 86.41%	28,000 $532,000
Q4 2021 Feb 14, 2022	BUY	$16.93 - $26.82 $3.49 Million - $5.52 Million	206,000 New	206,000 $4.64 Million

12.3M

229K

138K

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $10.9M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of Altium Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Altium Capital Management LP with notifications on news.